-

Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time). The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference.

To listen to the conference call, please dial (866) 374-5140 (US/Canada) or (404) 400-0571 (International) and use the confirmation number "41691074#" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk. Dexcom releases 2026 edition of its State of Type 2 Repo...

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer...

Dexcom Appoints Glenn Boehnlein to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world’s leading medical technology...
Back to Newsroom